Clearance of Yellow Tattoo Ink With a Novel 532-nm Picosecond Laser

Clearance of Yellow Tattoo Ink With a Novel 532-nm Picosecond Laser
复制标题

DOI:
10.1002/lsm.22354
复制
发表时间:
2015-04-01
影响因子:
2.4
通讯作者:
Geronemus, Roy G.
Geronemus, Roy G.
中科院分区:
医学3区
文献类型:
--
作者:
Alabdulrazzaq, Hamad;Brauer, Jeremy A.;Geronemus, Roy G.

文献摘要

被引文献

相似文献

背景和目的:虽然技术和纹身去除方法在不断发展,但黄色素的清除仍然具有挑战性,通常不会成功。我们描述了一个包含黄色墨水的六个纹身的病例系列,用倍频的Nd:YAG532 nm皮秒激光成功地治疗了这个病例系列。研究设计/材料和方法:六个受试者参与了含有黄色素的多彩纹身的治疗。采用倍频532 nm皮秒激光进行治疗,治疗间隔6~8周。结果:1例患者一次治疗后完全清除治疗部位,5例患者需要24次治疗才能达到75%以上的清除。停机时间最短,任何治疗部位都没有观察到疤痕或皮肤纹理变化。结论:这是第一个使用皮秒脉冲倍频Nd:YAG532 nm激光有效和一致地减少黄色纹身墨水的病例系列。治疗耐受性良好,受试者取得了积极的结果。这是一个正在进行的临床试验中的一个小型观察性病例系列,未来需要进行更大样本量和比较组的研究。激光外科医生。2015年,47:285-288。(C)2015年威利期刊公司。
Background and Objectives:Although technology and tattoo removal methods continue to evolve, yellow pigment clearance continues to be challenging and usually unsuccessful. We describe a case series of six tattoos containing yellow ink, successfully treated with a frequency-doubled Nd:YAG 532-nm picosecond laser.Study Design/Materials and Methods:Case series with six subjects participating for the treatment of multicolored tattoos that contain yellow pigment. Treatments performed with a frequency-doubled Nd:YAG 532-nm picosecond laser at 6-8 week intervals.Results:One subject achieved complete clearance of the treated site after one session, and five subjects required 24 treatments to achieve over 75% clearance. Minimal downtime was experienced, and no scarring or textural skin changes were observed in any of the treated sites.Conclusions:This is the first case series that demonstrates effective and consistent reduction of yellow tattoo ink using a frequency doubled Nd:YAG 532-nm laser with a picosecond pulse duration. Treatments were well tolerated and subjects had positive outcomes. This is a small observational case series from an ongoing clinical trial, and studies with a larger sample size and comparative group are needed in the future. Lasers Surg. Med. 47:285-288, 2015. (C) 2015 Wiley Periodicals, Inc.